Description

Drug Classification:

Olanzapine + Fluoxetine HCl Capsules belong to the class of drugs known as antipsychotics and antidepressants. This combination medication provides synergistic effects, targeting both psychotic symptoms and depressive episodes, making it particularly effective in treating conditions such as bipolar disorder and treatment-resistant depression.

Formulations:

• Olanzapine + Fluoxetine HCl Capsules:
  • Strengths: Available in formulations containing Olanzapine 3mg + Fluoxetine 25mg and Olanzapine 6mg + Fluoxetine 25mg.
  • Product Form: Oral capsules for easy administration.
  • Packing Specs: Each pack contains 14 capsules.

Indications:

Olanzapine + Fluoxetine HCl Capsules are indicated for the treatment of the following conditions:

• Bipolar Disorder: This medication is effective in managing acute depressive episodes associated with bipolar I disorder, as well as for preventing depressive relapse.
• Treatment-Resistant Depression: Olanzapine + Fluoxetine combination therapy is indicated for the treatment of treatment-resistant depression, providing relief from symptoms that have not responded adequately to other antidepressant medications.
• Psychotic Disorders: In addition to its antidepressant effects, olanzapine also addresses psychotic symptoms, making this combination suitable for individuals with co-occurring depressive and psychotic features.

Usage:

• Olanzapine + Fluoxetine HCl Capsules should be taken orally, swallowed whole with water, with or without food.
• It is important to adhere to the prescribed dosage and dosing schedule as directed by a healthcare professional.
• Patients should not discontinue this medication abruptly, as this may lead to withdrawal symptoms or disease recurrence. Any changes in dosage or treatment plan should be discussed with a healthcare provider.

Dosage:

• The recommended starting dose of Olanzapine + Fluoxetine HCl Capsules varies depending on the individual’s condition and previous treatment history.
• Dosage adjustments may be made based on clinical response and tolerability, under the guidance of a healthcare professional.

Pharmacokinetics:

• Olanzapine and fluoxetine are both extensively metabolized in the liver, primarily by the cytochrome P450 enzyme system.
• The pharmacokinetics of this combination medication are influenced by factors such as hepatic function, drug interactions, and individual patient characteristics.

Pharmacodynamics:

• Olanzapine exerts its antipsychotic effects through its antagonism of dopamine and serotonin receptors in the central nervous system, helping to alleviate psychotic symptoms such as hallucinations and delusions.
• Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), increases serotonin levels in the brain by inhibiting its reuptake, thereby improving mood and reducing depressive symptoms.

Side Effects:

• Common side effects associated with Olanzapine + Fluoxetine HCl Capsules may include drowsiness, dizziness, weight gain, dry mouth, and constipation.
• Less common but potentially serious side effects may include extrapyramidal symptoms, metabolic disturbances, and serotonin syndrome.
• Patients should be monitored closely for adverse reactions, and any concerning symptoms should be reported to a healthcare provider promptly.

Trust in the efficacy and safety of Olanzapine + Fluoxetine HCl Capsules from AIT Pharmaceuticals Division. Whether you are managing bipolar disorder, treatment-resistant depression, or psychotic symptoms, our product offers a comprehensive treatment approach to help you achieve symptom control and improve your quality of life. For more information, please visit our website or consult your healthcare provider.